Connect your AI

JBIO JBIO Operating lease liabilities

Operating lease liabilities at other companies

Vera TherapeuticsVERA

——

AnaptysBio, Inc.ANAB

——

Alumis Inc.ALMS

——

Oruka Therapeutics, Inc.ORKA

——

TG TherapeuticsTGTX

——

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

Market cap$1.33B—

Enterprise value$1.28B—

Returns & leverage

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is JBIO's operating lease liabilities?: JBIO (JBIO) reported operating lease liabilities of -$29K in Q1 2026.